Pharmaceutical

Zymeworks licenses new drug discovery platform from Innovative Targeting Solutions Zymeworks, a biotech company working on bispecific antibodies, has signed a licensing deal with Innovative Targeting Solutions (ITS) for HuTARG, which works as a protein engineering platform, and is the first fully mammalian tech that has the ability to generate antibody diversity in vitro via RAG1/RAG2 mediated V(D)J recombination. The deal states that Zymeworks will pay an undisclosed amount for tech license fee to get hold of ITS’s HuTARG drug discovery platform. NYU Langone Medical Center and Vedanta to codevelop microbiome-based cancer immunotherapies A partnership between Vedanta B...